Pregnancy vitamin D supplementation and offspring bone mineral density in childhood
Pregnancy vitamin D supplementation and offspring bone mineral density in childhood
Background: findings from the Maternal Vitamin D Osteoporosis Study (MAVIDOS) trial demonstrated a positive effect of gestational cholecalciferol supplementation on offspring bone mineral density (BMD) at age 4 y. Demonstrating the persistence of this effect is important to understanding whether maternal vitamin D supplementation could be a useful public health strategy to improving bone health.
Objectives: we investigated whether gestational vitamin D supplementation increases offspring BMD at ages 6–7 y in an exploratory post-hoc analysis of an existing trial.
Methods: in the MAVIDOS randomized controlled trial, pregnant females <14 wk’ gestation with a singleton pregnancy and serum 25-hydroxyvitamin D 25–100nmol/l at 3 United Kingdom hospitals (Southampton, Sheffield, and Oxford) were randomly assigned to either 1000 IU/d cholecalciferol or placebo from 14 to 17-wk gestation until delivery. Offspring born at term to participants recruited in Southampton were invited to the childhood follow-up at ages 4 and 6–7 y. The children had a dual-energy X-ray absorptiometry (DXA, Hologic discovery) scan of whole-body-less-head (WBLH) and lumbar spine, from which bone area, bone mineral content (BMC), BMD, and bone mineral apparent density (BMAD) were derived. Linear regression was used to compare the 2 groups adjusting for age, sex, height, weight, duration of consumption of human milk, and vitamin D use at 6–7 y.
Results: a total of 454 children were followed up at ages 6–7 y, of whom 447 had a usable DXA scan. Gestational cholecalciferol supplementation resulted in higher WBLH BMC [0.15 SD, 95% confidence interval (CI): 0.04, 0.26], BMD (0.18 SD, 95% CI: 0.06, 0.31), BMAD (0.18 SD, 95% CI: 0.04, 0.32), and lean mass (0.09 SD, 95% CI: 0.00, 0.17) compared with placebo. The effect of pregnancy cholecalciferol on bone outcomes was similar at ages 4 and 6–7 y.
Conclusions: supplementation with cholecalciferol 1000 IU/d during pregnancy resulted in greater offspring BMD and lean mass in mid-childhood compared with placebo in this exploratory post-hoc analysis. These findings suggest that pregnancy vitamin D supplementation may be an important population health strategy to improve bone health.
Trial registration number: this trial was registered at the ISRCTN (https://doi.org/10.1186/ISRCTN82927713) as 82927713 and EUDRACT (https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001716-23/results) as 2007-001716-23.
Moon, Rebecca J.
954fb3ed-9934-4649-886d-f65944985a6b
D'Angelo, Stefania
13375ecd-1117-4b6e-99c0-32239f52eed6
Curtis, Elizabeth M.
12aba0c3-1e9e-49ef-a7e9-3247e649cdd6
Ward, Kate A.
39bd4db1-c948-4e32-930e-7bec8deb54c7
Crozier, Sarah R.
9c3595ce-45b0-44fa-8c4c-4c555e628a03
Schoenmakers, Inez
b25daaac-b388-467c-a514-3a6f5029bc2e
Kassim Javaid, M.
12781b29-34fa-4158-837b-daf452b8d4ed
Bishop, Nicholas J.
5ba07beb-3ba4-44e0-98bf-7b5748ec4ae6
Godfrey, Keith M.
0931701e-fe2c-44b5-8f0d-ec5c7477a6fd
Cooper, Cyrus
e05f5612-b493-4273-9b71-9e0ce32bdad6
Harvey, Nicholas C.
ce487fb4-d360-4aac-9d17-9466d6cba145
Moon, Rebecca J.
954fb3ed-9934-4649-886d-f65944985a6b
D'Angelo, Stefania
13375ecd-1117-4b6e-99c0-32239f52eed6
Curtis, Elizabeth M.
12aba0c3-1e9e-49ef-a7e9-3247e649cdd6
Ward, Kate A.
39bd4db1-c948-4e32-930e-7bec8deb54c7
Crozier, Sarah R.
9c3595ce-45b0-44fa-8c4c-4c555e628a03
Schoenmakers, Inez
b25daaac-b388-467c-a514-3a6f5029bc2e
Kassim Javaid, M.
12781b29-34fa-4158-837b-daf452b8d4ed
Bishop, Nicholas J.
5ba07beb-3ba4-44e0-98bf-7b5748ec4ae6
Godfrey, Keith M.
0931701e-fe2c-44b5-8f0d-ec5c7477a6fd
Cooper, Cyrus
e05f5612-b493-4273-9b71-9e0ce32bdad6
Harvey, Nicholas C.
ce487fb4-d360-4aac-9d17-9466d6cba145
Moon, Rebecca J., D'Angelo, Stefania, Curtis, Elizabeth M., Ward, Kate A., Crozier, Sarah R., Schoenmakers, Inez, Kassim Javaid, M., Bishop, Nicholas J., Godfrey, Keith M., Cooper, Cyrus and Harvey, Nicholas C.
,
the MAVIDOS Trial Group
(2024)
Pregnancy vitamin D supplementation and offspring bone mineral density in childhood.
American Journal of Clinical Nutrition.
(doi:10.1016/j.ajcnut.2024.09.014).
Abstract
Background: findings from the Maternal Vitamin D Osteoporosis Study (MAVIDOS) trial demonstrated a positive effect of gestational cholecalciferol supplementation on offspring bone mineral density (BMD) at age 4 y. Demonstrating the persistence of this effect is important to understanding whether maternal vitamin D supplementation could be a useful public health strategy to improving bone health.
Objectives: we investigated whether gestational vitamin D supplementation increases offspring BMD at ages 6–7 y in an exploratory post-hoc analysis of an existing trial.
Methods: in the MAVIDOS randomized controlled trial, pregnant females <14 wk’ gestation with a singleton pregnancy and serum 25-hydroxyvitamin D 25–100nmol/l at 3 United Kingdom hospitals (Southampton, Sheffield, and Oxford) were randomly assigned to either 1000 IU/d cholecalciferol or placebo from 14 to 17-wk gestation until delivery. Offspring born at term to participants recruited in Southampton were invited to the childhood follow-up at ages 4 and 6–7 y. The children had a dual-energy X-ray absorptiometry (DXA, Hologic discovery) scan of whole-body-less-head (WBLH) and lumbar spine, from which bone area, bone mineral content (BMC), BMD, and bone mineral apparent density (BMAD) were derived. Linear regression was used to compare the 2 groups adjusting for age, sex, height, weight, duration of consumption of human milk, and vitamin D use at 6–7 y.
Results: a total of 454 children were followed up at ages 6–7 y, of whom 447 had a usable DXA scan. Gestational cholecalciferol supplementation resulted in higher WBLH BMC [0.15 SD, 95% confidence interval (CI): 0.04, 0.26], BMD (0.18 SD, 95% CI: 0.06, 0.31), BMAD (0.18 SD, 95% CI: 0.04, 0.32), and lean mass (0.09 SD, 95% CI: 0.00, 0.17) compared with placebo. The effect of pregnancy cholecalciferol on bone outcomes was similar at ages 4 and 6–7 y.
Conclusions: supplementation with cholecalciferol 1000 IU/d during pregnancy resulted in greater offspring BMD and lean mass in mid-childhood compared with placebo in this exploratory post-hoc analysis. These findings suggest that pregnancy vitamin D supplementation may be an important population health strategy to improve bone health.
Trial registration number: this trial was registered at the ISRCTN (https://doi.org/10.1186/ISRCTN82927713) as 82927713 and EUDRACT (https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001716-23/results) as 2007-001716-23.
Text
MAVIDOS 6y AJCN Revision 2 FINAL clean
- Accepted Manuscript
Text
1-s2.0-S0002916524007469-main
- Proof
More information
Accepted/In Press date: 16 September 2024
e-pub ahead of print date: 18 September 2024
Additional Information:
For the purpose of Open Access, the author has applied a Creative Commons Attribution (CC BY) license to any Author Accepted Manuscript version arising from this submission.
Identifiers
Local EPrints ID: 494689
URI: http://eprints.soton.ac.uk/id/eprint/494689
ISSN: 0002-9165
PURE UUID: 95c03d39-8d79-4e99-b2d4-1a32a146ae98
Catalogue record
Date deposited: 14 Oct 2024 16:38
Last modified: 19 Oct 2024 01:51
Export record
Altmetrics
Contributors
Author:
Rebecca J. Moon
Author:
Stefania D'Angelo
Author:
Inez Schoenmakers
Author:
M. Kassim Javaid
Author:
Nicholas J. Bishop
Corporate Author: the MAVIDOS Trial Group
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics